SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Andrén Ove)
 

Sökning: WFRF:(Andrén Ove) > PD-L1 Expression in...

PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes

Davidsson, Sabina (författare)
Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
Carlsson, Jessica, 1984- (författare)
Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Urology
Giunchi, Francesca (författare)
Molecular Pathology Laboratory, Addarii Institute of Oncology, Department of Specialist Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy
visa fler...
Harlow, Alyssa (författare)
Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA
Kirrander, Peter, 1978- (författare)
Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
Rider, Jennifer (författare)
Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA
Fiorentino, Michelangelo (författare)
Molecular Pathology Laboratory, Addarii Institute of Oncology, Department of Specialist Diagnostic and Experimental Medicine, University of Bologna, Bologna, Italy
Andrén, Ove, 1963- (författare)
Örebro universitet,Institutionen för medicinska vetenskaper,Department of Urology
visa färre...
 (creator_code:org_t)
Elsevier, 2019
2019
Engelska.
Ingår i: European Urology Oncology. - : Elsevier. - 2588-9311. ; 2:2, s. 214-221
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: It has been hypothesized that PD-L1 expression in tumor cells and tumor-infiltrating immune (TII) cells may contribute to tumor progression by inhibiting antitumor immunity.Objective: To investigate the association between PD-L1 expression in tumor cells and TII cells and clinical outcomes in penile cancer.Design, setting, and participants: A cohort of 222 men treated for penile squamous cell carcinoma (SqCC) at Örebro University Hospital between 1984 and 2008 with long-term follow-up (median 34 mo) was evaluated for PD-L1 expression in tumor cells and TII cells via immunohistochemistry.Outcome measurements and statistical analysis: Association between clinicopathological features and PD-L1 expression was estimated using χ2 and Fisher's exact tests. For survival analyses, Kaplan-Meier curves with log-rank tests and multivariate Cox proportional hazards regression models were used.Results and limitations: We found that 32.1% of the tumors and 64.2% of the TII cells expressed PD-L1. Our data demonstrate that penile SqCC patients with PD-L1–positive tumor cells or TII cells are at significant risk of lower cancer-specific survival and that the prognostic value of PD-L1 expression was strongest for tumor cell positivity. The use of tissue microarrays rather than whole sections may be viewed as a limitation.Conclusions: Tumor PD-L1 expression independently identifies penile SqCC patients at risk of poor clinical outcomes.Patient summary: We investigated how many patients with penile cancer had tumors that manufactured PD-L1, a protein that decreases the ability of the immune system to fight cancer. We found that up to one-third of penile tumors make this protein. Patients whose tumors make PD-L1 have more aggressive penile cancer and worse clinical outcomes.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Penile squamos cell carcinoma
Immunohistochemistry
PD-L1

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy